Clinical Trials has recently completed a Phase 3 clinical trial to study the use of BSN175 as a treatment for metabolic syndrome and diabetes.



We’re taking aim at chronic disease and we won’t give up until we conquer.

Biospherics is a leader in the application of combination drugs to complex diseases, molecular simulations and modeling, and research in the metabolic syndrome.  The Company’s newest lead candidates are BSN908 for treatment of abdominal aortic aneurysm, and BSN272, for reducing triglycerides, cholesterol and atherosclerosis.  Biospherics also has phase 3 clinical trial results with BSN175, being developed as an oral treatment for glycemic control in patients with metabolic syndrome and diabetes.  For more on treatment of these diseases, see the pipeline.